RT Journal Article
SR Electronic
T1 A Believer’s Overview of Cancer Immunosurveillance and Immunotherapy
JF The Journal of Immunology
JO J. Immunol.
FD American Association of Immunologists
SP 385
OP 391
DO 10.4049/jimmunol.1701302
VO 200
IS 2
A1 Finn, Olivera J.
YR 2018
UL http://www.jimmunol.org/content/200/2/385.abstract
AB The field of tumor immunology has grown around the idea that one of the important roles of the immune system is to eliminate cancer. This idea was difficult to reconcile with the accepted notion that the immune system evolved to distinguish self from nonself and therefore tumors derived from self-tissues would not be recognized. Lack of appropriate animal models prevented experimental testing of cancer immunosurveillance. This changed with the realization that the immune system evolved to recognize danger and with the advent of mouse models deficient in one or more immune function, which showed predicted increases in susceptibility to cancer. Simultaneously, technical advances that enabled the study of the human immune system provided data for the existence of tumor-specific T cells and Abs and led to molecular identification of tumor Ags, fully validating the cancer immunosurveillance hypothesis. Immunotherapy designed to strengthen cancer immunosurveillance has achieved unprecedented clinical successes.